136232-95-6

Usage

Uses

Used in Opioid Addiction Treatment:
Buprenorphine hydrochloride is used as a therapeutic agent for opioid use disorder, offering a safer and more effective alternative to full agonist opioids. Its partial agonist properties allow for the management of withdrawal symptoms and cravings, facilitating the recovery process for patients with opioid dependence.
Used in Chronic Pain Management:
In the field of pain management, buprenorphine hydrochloride is utilized as an analgesic agent for the treatment of moderate to severe chronic pain. Its long-acting nature and once-daily dosing regimen make it a convenient and effective option for patients requiring ongoing pain relief.
Used in Pharmaceutical Formulations:
Buprenorphine hydrochloride is commonly used as an active pharmaceutical ingredient in various formulations, such as sublingual tablets and films. These formulations facilitate easy administration and absorption, ensuring consistent and controlled drug delivery to patients in need of opioid addiction treatment or chronic pain management.

Upstream product

• 1489-69-6 Cyclopropanecarboxaldehyde 
• 78715-23-8 norbuprenorphine 
• 52485-79-7 Buprenorphine 
• 115-37-7 thebaine 
• 15358-23-3 (5α,7β)-4,5-epoxy-17-methyl-3,6-dimethoxy-7β-acetyl-6,14-ethenomorphinan 
• 16196-83-1 7α-acetyl-6,14-endoethanotetrahydrothebaine 
• 22152-80-3 [5α,7α]-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3,6-dimethoxy-α,17-dimethyl-6,14-ethenomorphinan-7-methanol 
• 22151-78-6 (S)-2-((4R,4aS,6R,7R,7aR,12bS)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-6-yl)-3,3-dimethylbutan-2-ol 
• 16196-82-0 7-acetyl-6,14-endo-ethano-6,7,8,14-tetrahydrothebaine 
• 15358-22-2 thevinone 
• 127131-05-9 1-[(5α,7α)-17-(cyclopropylmethyl)-4,5-epoxy-3,6-dimethoxy-6,14-ethanomorphinan-7-yl]ethenone 
• 152427-77-5 (5R,6R,7S,9R,13S,14S)-7-Acetyl-17-cyclopropylmethyl-4,5-epoxy-18,19-dihydro-3,6-dimethoxy-6,14-ethanomorphinan 
• 155203-04-6 17-cyclopropylmethyl-4,5α-epoxy-6α,14α-etheno-7α-(1-hydroxy-1,2,2-trimethylpropyl)-3,6β-dimethoxymorphinan 
• 16524-65-5 [5α,7α(S)]-17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3,6-dimethoxy-α-methyl-6,14-ethenomorphinan-7-methanol 

Downstream Products

• 1750-45-4 6-hydroxychlorzoxazone 
• 97203-04-8 21-cyclopropyl-7α-<2-(3,3-dimethyl-1-butenyl)>-6,14-endo-ethanotetrahydrooripavine 
• 91423-89-1 C₂₈H₃₇NO₃ 
• 5719-85-7 4-hydroxytolbutamide 

Related news

Effects of sedation with acepromazine maleate and buprenorphine hydrochloride (cas 136232-95-6) on femoral artery blood flow in healthy dogs09/04/2019

The purpose of this study was to qualify and quantify the femoral artery blood flow by duplex Doppler ultrasonography (DDU) in healthy dogs, before and after the administration of a combination of acepromazine maleate and buprenorphine hydrochloride (ACP–BPN). Seven healthy adult mongrel dogs a...detailed

buprenorphine hydrochloride (cas 136232-95-6) induces apoptosis in NG108-15 nerve cells09/02/2019

A morphine alkaloid derivative, buprenorphine hydrochloride, induces apoptosis in NG108-15 cells. Apoptosis was detected mainly by apoptosis-specific DNA fragmentation and morphological changes. This apoptosis was dose-dependent and the time-course experiment indicated that DNA fragmentation occ...detailed

Fabrication of an ultrasensitive impedimetric buprenorphine hydrochloride (cas 136232-95-6) biosensor from computational and experimental angles08/31/2019

For the first time, an ultrasensitive impedimetric buprenorphine hydrochloride (BN) biosensor based on immobilization of bovine serum albumin (BSA) onto multi-walled carbon nanotubes (MWCNTs)/glassy carbon electrode (BSA/MWCNTs/GCE) has been developed using initial characterization by computatio...detailed

Relevant academic research and scientific papers

Preparation of 6,14-Ethenomorphinan Derivatives

Dihydronorthevinone (2b) was prepared from dihydrothevinone (2a) with diethyl azodicarboxylate (DEAD) and transformed into a number of new N-substituted dihydronorthevinone derivatives (2c-2g).Grignard reactions of the new compounds with methylmagnesium iodide and tert-butyl-magnesium chloride were studied.O-Demethylation of 3a-3j resulted in the corresponding N-substituted buprenorphine and diprenorphine analogs 4a-4j. - Keywords: Buprenorphine; Diprenorphine; Dihydronorthevinone; N-Substituted Dihydronorthevinone; Grignard-reactions; Morphine alkaloids; O-Demethylation with DIBAL.

Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450

The invention relates to recombinant host cells that expresses one or more genes encoding a cytochrome P450 enzyme capable of N-demethylating and/O-demethylating reticuline and/or derivatives thereof, and also methods of producing a N-demethylated and/or O-demethylated reticuline and/or derivatives thereof, comprising cultivating the recombinant host of the invention in a culture medium under conditions in which the one or more genes encoding the cytochrome P450 enzymes is/are expressed. The reticuline and derivatives thereof are useful for providing access to naturally unavailable and chemically difficult-to-produce starting materials for opioids.

DEUTERATED COMPOUND AND MEDICAL USE THEREOF

The present invention relates to a compound represented by formula I and a non-toxic pharmaceutically acceptable salt thereof. In formula (I), R1 is H, CH3 or deuterated methyl (CD3); R2 is CH3 or CH2CH3; R3, R4 and R5 are each independently H or deuterium (D); when R1 is H or CH3, at least one of R3, R4 and R5 is D.

PREPARATION OF BUPRENORPHINE

Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.

PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS

The present invention is directed to a process for the preparation of opioid compounds such as buprenorphine, naltrexone, naloxone, nalbuphone, nalbuphine, and the like.

PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS

The present invention is directed to a process for the preparation of opioid compounds such as buprenorphine, naltrexone, naloxone, nalbuphone, nalbuphine, and the like.

AN IMPROVED PROCESS FOR THE PREPARATION OF MORPHINANE ANALOGUES

The present invention relates to an improved process for preparing morphinane analogues of formula (1) wherein the substituents R1, R2, R2a, R3, R4, R5 and Y have the meanings as defined in the specifications.

PREPARATION OF OPIATE ANALGESICS BY REDUCTIVE ALKYLATION

A process for preparing a compound of formula (A), (B) or (C): wherein P is H, CH3 or a hydroxyl protecting group; X is O, a protected ketone, OH, a protected hydroxyl group or H; Y is OH, a protected hydroxyl group or H; W is C(CH3)2OH, C(CH3)(C(CH3)3)OH or COCH3; Z is C2-C10 alkyl or C2-C10 arylalkyl; and ′ is a. single bond or a double bond, is disclosed. The process is a reductive alkylation in the presence of hydrogen and a reductive alkylation catalyst.

Pharmaceutical compositions for suppository

A pharmaceutical composition for suppository which comprises buprenorphine or its pharmaceutically acceptable acid added salt as the active ingredient and a mixed base composed of 70 to 95 wt.% of polyethylene glycol with average molecular weight of 200 to 20,000 and 30 to 5 wt.% of propylene glycol.